Gout in Solid Organ Transplantation

@article{Stamp2012GoutIS,
  title={Gout in Solid Organ Transplantation},
  author={Lisa K. Stamp and Martin Searle and John L O'Donnell and Peter T. Chapman},
  journal={Drugs},
  year={2012},
  volume={65},
  pages={2593-2611}
}
Hyperuricaemia occurs in 5–84% and gout in 1.7–28% of recipients of solid organ transplants. Gout may be severe and crippling, and may hinder the improved quality of life gained through organ transplantation. Risk factors for gout in the general population include hyperuricaemia, obesity, weight gain, hypertension and diuretic use. In transplant recipients, therapy with ciclosporin (cyclosporin) is an additional risk factor.Hyperuricaemia is recognised as an independent risk factor for… 
The Management of Gout in Renal Disease.
Managing new-onset gout in pediatric renal transplant recipients: when, how, to what extent.
  • F. Assadi
  • Medicine, Biology
    Journal of nephrology
  • 2013
TLDR
Proper management is aimed at lowering serum uric acid level below 6.0 mg/dL with xanthine oxidase inhibitors such as allopurinol or febuxostat, and Pegloticase is indicated for patients with severe gout in whom allopURinol and febUXostat have not been effective or tolerated.
Pancytopenia caused by allopurinol and azathioprine interaction in a heart transplant patient: a case report
TLDR
The association between gout and solid organ transplantation, recognition of the risks of medication interaction as well as communication amongst health care providers and between providers and their patients is paramount.
Drug-induced hyperuricaemia and gout.
TLDR
Increased awareness of drugs that can induce hyperuricaemia and gout, and monitoring and prevention are key elements for reducing the morbidity related to drug-induced hyperurICAemia and Gout.
Efficacy of Losartan in Treatment of Hyperuricemia in renal transplant recipients
TLDR
Losartan can be a useful agent for treatment of hyperuricemia in RTRs without significant side effects and it was found that there was no significant decline in glomerular filtration rate in the Losartan group.
[Current epidemiology of gout].
  • Barbara Ankli
  • Medicine, Biology
    Therapeutische Umschau. Revue therapeutique
  • 2016
TLDR
Gout is the most common inflammatory arthritis in adults nowadays and Reasons for the rise in prevalence are longevity, dietary habits and the high prevalence of patients with chronic kidney disease in the general population.
Could Uric acid have a Pathogenic Role in Chronic Allograft Dysfunction
TLDR
A controlled clinical trial would be the best approach to determine the effect of uric acid lowering treatment on the development of CAD and long term graft function.
Treatment of hypertension due to immunosuppressive therapy after solid organ transplantation - pharmacological approach.
TLDR
E epidemiology, pathogenetic mechanisms and treatment of hypertension induced by immunosuppressive medication, focused on drugs belonging to the following groups: calcineurin inhibitors (CNI), the inhibitors of the mammalian target of rapamycin (mTOR) and glucocorticosteroids (GS).
Prevention of complications from use of conventional immunosuppressants: a critical review
TLDR
In this review, the categories of synthetic immunosuppressive agents more frequently and conventionally used in clinical nephrology are considered: glucocorticoids, Aalkylating agents (cyclophosphamide, chlorambucil), purine synthesis inhibitors (azathioprine, mycophenolate salts) and calcineurin inhibitors (cyclosporine, tacrolimus).
...
1
2
3
4
...

References

SHOWING 1-10 OF 300 REFERENCES
HYPERURICEMIA, GOUT, AND RENAL FUNCTION AFTER LIVER TRANSPLANTATION
TLDR
Treatment with allopurinol results in a significant reduction in serum creatinine in patients with gout and in those with hyperuricemia and renal impairment, which is a recognized complication of renal and cardiac transplantation.
Fenofibrate: a new treatment for hyperuricaemia and gout?
TLDR
Three cases in which micronised fenofibrate, a single dose formulation of the drug, was initiated in patients with established gout and hyperuricaemia, with and without coexisting hyperlipidaemia are reported.
Post-cardiac transplantation gout: incidence of therapeutic complications.
  • A. Wluka, P. Ryan, D. Esmore
  • Medicine
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • 2000
Hyperuricemia after renal transplantation.
Long-term efficacy of hyperuricaemia treatment in renal transplant patients.
  • F. Perez-Ruiz, P. Gomez-Ullate, J. Nolla
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2003
TLDR
Benziodarone at doses >75 mg/day was more effective than allopur inol in reducing serum uric acid levels and also reduced the risk of azathioprine-allopurinol interactions.
Management of Acute and Chronic Gouty Arthritis
TLDR
The use of recombinant urate oxidase in patients with chronic gout is limited by the need for parenteral administration, the potential antigenicity and production of anti-urate oxidase antibodies, and declining efficacy.
The incidence of gout in renal transplant recipients.
Hyperuricaemia and gout.
  • M. Shipley
  • Medicine
    The journal of the Royal College of Physicians of Edinburgh
  • 2011
TLDR
Improved understanding of the membrane transporters involved in urate excretion in the kidney and the genes that control them and of the way that sodium urate crystals cause inflammation via the innate immune system and the inflammasome offers hope for new therapeutic approaches.
Hyperuricaemia in cyclosporin-treated patients: GFR-related effect.
  • R. Zürcher, H. Bock, G. Thiel
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 1996
TLDR
Hyperuricaemia in CsA-treated transplant patients can be attributed to the cyclosporin-associated decrease of GFR, and there is no evidence for impaired tubular handling of uric acid, induced by a C sA-specific tubulotoxic effect.
...
1
2
3
4
5
...